- Market Size (2026)
- USD 230.38 Bn
- Forecast (2036)
- USD 248.39 Bn
- CAGR (2026 to 2036)
- 30%
Gene Therapy in CNS Disorder Market Size, Market Forecast and Outlook By FMI
The gene therapy in cns disorder market was valued at USD 13.9 billion in 2025. The market is set to reach USD 18.0 billion by 2026-end and grow at a CAGR of 30.0% between 2026-2036 to reach USD 248.4 billion by 2036. In Vivo Gene Therapy will dominate with a 63.5% share, while Alzheimer's Disease will lead with a 36.8% share.
Summary of the Gene Therapy in CNS Disorder Market
- Demand and Growth Drivers
- Demonstrated clinical success of gene therapy in monogenic CNS disorders, exemplified by approved therapies for spinal muscular atrophy, has established the commercial and regulatory precedent for CNS gene therapy product development and launch.
- Advancing pipeline of AAV vector based gene therapies targeting Huntington disease, ALS, Parkinson disease, and rare pediatric neurological conditions is expected to generate multiple product approvals and significant market expansion through 2036.
- Manufacturing scalability investment by gene therapy developers and contract manufacturing organizations is addressing the production capacity constraints that have historically limited gene therapy commercial availability.
- Product and Segment View
- In Vivo Gene Therapy holds 63.5% of the Gene Type segment in 2026, reflecting the predominance of direct CNS delivery approaches using viral vector administration to transduce neural tissue in situ.
- Vector Type segment is led by Adeno-Associated Virus (AAV) at 49.6% driven by the well-established safety profile, neural tropism and regulatory precedent of AAV based vectors for CNS gene therapy applications.
- The Delivery Method slice shows that 58.9% Viral Vectors is indicative of the leading therapeutic indication driving CNS gene therapy clinical development and revenue.
- Geography and Competitive Outlook
- The USA leads growth at 32% CAGR through 2036, reflecting concentrated gene therapy research infrastructure, FDA regulatory pathways that support accelerated approval for serious CNS conditions, and the highest willingness to pay for curative gene therapy products.
- China at 32% reflects substantial government investment in gene therapy manufacturing, expanding clinical trial activity in CNS indications, and regulatory pathway modernization that supports gene therapy product approval.
- Companies with late stage CNS gene therapy pipeline assets, proprietary AAV capsid technology, and scalable manufacturing capability are positioned to capture transformative revenue as product approvals accumulate through the forecast period.
- Analyst Opinion
- Sabyasachi Ghosh, Principal Consultant at FMI says, 'The CNS gene therapy market represents the highest growth opportunity in pharmaceutical development through 2036. Companies that solve the dual challenge of efficient blood brain barrier crossing and durable transgene expression in neural tissue will capture transformative revenue in indications ranging from rare monogenic disorders to prevalent neurodegenerative conditions. Manufacturing scalability and pricing sustainability remain the critical commercial barriers to broad market access.'
- The gene therapy in cns disorder market is transitioning toward more structured procurement and supply chain relationships.
- Adoption is increasing due to evolving regulatory requirements and commercial performance benchmarks.
- Demand is further supported by evolving standards across North America, Europe, and East Asia.
Key Takeaways, Market Size, and Forecast
- The gene therapy in cns disorder market was valued at USD 13.96 billion in 2025.
- By 2036, the Gene Therapy in CNS Disorder Market is expected to be worth USD 248.39 billion.
- From 2026 to 2036, the market is projected to expand at a CAGR of 30%.
- The market is projected to create an incremental opportunity of USD 230.38 billion between 2026 and 2036.
- In 2026, In Vivo Gene Therapy is expected to account for 63.5% of the Gene Type, driven by demonstrated clinical efficacy in monogenic CNS disorders using AAV vector delivery, with approved therapies for spinal muscular atrophy establishing the commercial and regulatory precedent for CNS gene therapy.
- USA (32%) and China (32%) are two of the fastest growing markets in the world.
Gene Therapy in CNS Disorder Market Definition
The gene therapy in CNS disorder market encompasses gene based therapeutic products designed to treat neurological and neurodegenerative disorders by delivering functional gene copies, gene silencing constructs, or gene editing components to cells of the central nervous system. Delivery approaches include in vivo viral vector administration and ex vivo cell based gene modification.
Gene Therapy in CNS Disorder Market Inclusions
Market scope covers all commercially marketed and late stage pipeline CNS gene therapy products categorized by Gene Type, Indication, Delivery Method, End User, Vector Type, Route of Administration. Revenue sizing spans the 2026 to 2036 forecast period.
Gene Therapy in CNS Disorder Market Exclusions
The scope does not include conventional small molecule or biologic drugs for CNS disorders, gene therapy products for non CNS indications, diagnostic genetic testing services, or basic research gene therapy tools not intended for clinical use.
Gene Therapy in CNS Disorder Market Research Methodology
- Primary Research: FMI analysts conducted interviews with manufacturers, specialists, and supply chain participants across key markets.
- Desk Research: Combined industry databases, regulatory filings, trade publications, and manufacturer disclosures.
- Market Sizing and Forecasting: Bottom up aggregation across segments, applications, and regions with adoption curve modeling.
- Data Validation: Cross checked quarterly against production statistics, trade data, and reported figures.
Why is the Gene Therapy in CNS Disorder Market Growing?
- Gene therapy is a commercially viable treatment modality for neurological conditions, as demonstrated by clinical proof of concept in spinal muscular atrophy and rare pediatric CNS disorders, attracting significant investment in CNS pipeline expansion.
- Advances in AAV capsid engineering, such as variants with enhanced ability to cross the blood brain barrier or improved tropism for neural cell types, are expanding the range of CNS diseases that can be treated by systemically delivered gene therapy.
- The USA and China (both 32% CAGR) are leading the growth reflecting concentrated gene therapy R&D investment, regulatory pathway development and manufacturing infrastructure expansion.
As clinical development programs mature and product approvals increase, the gene therapy market for CNS disorders is poised for exceptional growth. In vivo gene therapy is the most common therapeutic strategy that consists of 63.5% of the gene type segment, which delivers functional gene copies to neural tissue through viral vectors. AAV vectors account for 49.6% of the vector type segment, supported by their proven safety profile in CNS indications, tropism for neural cell types, and the regulatory precedent set by approved SMA gene therapy products.
The market’s 30.0% CAGR demonstrates the potential of gene therapy to transform the treatment of CNS disorders for which there is no effective pharmacotherapy today. Revenue growth is mainly fuelled by pipeline programmes for Huntington’s disease, amyotrophic lateral sclerosis, Parkinson’s, Alzheimer’s and rare paediatric neurodegenerative diseases. Each clinical program that is approved for commercialization adds a high value product to the commercial portfolio, with individual gene therapy products having the potential to generate annual revenues in excess of USD 1 billion.
The main commercial constraints are the scalability and manufacturing cost. The development of gene therapies depends on the manufacturing of specialized viral vectors at clinical grade purity and there is a limited capacity of AAV production which restricts the number of patients that can be treated per year. Translating clinical success into broad commercial access will require investment in large scale suspension cell culture manufacturing, analytical characterization methods and supply chain optimization. Currently, the per patient treatment costs of approved CNS gene therapies exceed USD 1 million, which present reimbursement challenges that require outcomes based contracting and installment payment models.
Market Segmentation Analysis
- In Vivo Gene Therapy accounts for 63.5% share in the Gene Type segment, backed by proven demand.
- Adeno-Associated Virus (AAV) accounts for 49.6% of the Vector Type segment, reflecting core buyer concentration.
- Viral Vectors at 58.9% of the Delivery Method segment reflects functional and logistical preferences.
The gene therapy in cns disorder market is segmented by Gene Type, Indication, Delivery Method, End User, Vector Type, Route of Administration.
Insights into the In Vivo Gene Therapy Gene Type Segment
In 2026, In Vivo Gene Therapy is expected to account for 63.5% of the Gene Type segment. This position reflects sustained demand where in vivo gene therapy has demonstrated consistent efficacy and cost effectiveness. Sub segments are differentiated by specifications and pricing. Procurement decisions prioritize supply reliability, regulatory compliance, and quality consistency.
Insights into the Adeno-Associated Virus (AAV) Vector Type Segment
Adeno-Associated Virus (AAV) holds 49.6% share in the Vector Type segment. Standardization and the growth of addressable markets support growth. Buyers want consistent performance, total cost of ownership and availability of technical support.
Gene Therapy in CNS Disorder Market Drivers, Restraints, and Opportunities
- Regulations create captive markets for products that comply with them.
- Cost pressures and supply constraints could squeeze margins.
- Application expansion offers incremental growth opportunities.
Regulatory mandates, changing requirements and competition across product segments and geographies are shaping the gene therapy in cns disorder market.
Clinical Proof of Concept and Regulatory Precedent
Demand is affected by the demonstrated success of approved CNS gene therapies, which established both clinical efficacy and regulatory approval pathways for the modality. The approval of onasemnogene abeparvovec for SMA provided proof-of-concept that AAV delivered gene therapy can yield durable clinical benefit in CNS disorders, driving investment in pipeline programs targeting a wide range of neurological conditions.
Manufacturing Scalability and Cost Barriers
Limited availability of GMP grade viral vector manufacturing capacity and high per dose production costs associated with current manufacturing processes are limiting growth. The production of AAV vectors at the scale and purity required for systemic CNS delivery remains technically challenging and capital intensive. To improve patient access, the manufacturing cost needs to be reduced by process optimization and increased capacity.
Capsid Engineering and Blood Brain Barrier Crossing
Advances in AAV capsid engineering to create vector variants with enhanced capacity to cross the blood brain barrier following systemic administration are fueling increased adoption . These engineered capsids enable strategies for intravenous delivery that circumvent the necessity for invasive intrathecal or intracranial vector administration, thereby expanding the eligible patient population and reducing the procedural risk.
Reimbursement Innovation for Curative Therapies
Growth reflects the emergence of new reimbursement models designed to accommodate the high upfront cost of potentially curative gene therapies. Mechanisms such as outcomes based contracting, annuity payment models, and government sponsored gene therapy funds are emerging to spread the financial impact of single dose curative treatments over multiple payer years and provide broader market access for approved products.
Analysis of Gene Therapy in CNS Disorder Market By Key Countries
.webp "Top Country Growth Comparison Gene Therapy In Cns Disorder Market Cagr (2026 2036)")
| Country | CAGR |
|---|---|
| USA | 32% |
| UK | 28% |
| France | 27% |
| Germany | 29% |
| Italy | 26% |
| South Korea | 31% |
| Japan | 26% |
| China | 32% |
| Australia - New Zealand | 28% |
| India | 25% |
- USA leads with 32% CAGR through 2036.
- China at 32% demonstrates sustained demand.
- UK (28%) reflects steady demand from established industries.
The global gene therapy in cns disorder market is projected to grow at 30% CAGR from 2026 to 2036. The analysis covers more than 30 countries.
Demand Outlook for Gene Therapy in CNS Disorder Market in the United States
The United States is expected to grow at 32.0% CAGR through 2036. The US market represents the primary revenue base for CNS gene therapy, with the highest willingness to pay for curative treatments, the most advanced FDA regulatory pathways for gene therapy products, and the concentration of gene therapy manufacturing and clinical development infrastructure.
- FDA accelerated approval pathways enable rapid market access for CNS therapies.
- Highest willingness to pay supports premium gene therapy pricing.
- Concentrated gene therapy R&D infrastructure supports earliest product development.
Future Outlook for Gene Therapy in CNS Disorder Market in the United Kingdom
The United Kingdom is expected to grow at 28.0% CAGR through 2036. NHS England's specialized commissioning for advanced therapy medicinal products, combined with strong academic gene therapy research at institutions like UCL and Oxford, positions the UK as an early adopter of approved CNS gene therapies with structured public sector reimbursement pathways.
- NHS specialized commissioning provides reimbursement for ATMPs.
- Academic gene therapy research programs support clinical translation.
- UK Rare Diseases Framework supports gene therapy development for neurogenetic conditions.
Opportunity Analysis of Gene Therapy in CNS Disorder Market in Germany
Germany is expected to grow at 29.0% CAGR through 2036. Germany's AMNOG early benefit assessment process provides structured market access for gene therapies at launch, with university hospital gene therapy centers and the German Gene Therapy Society supporting clinical adoption of approved CNS gene therapy products.
- AMNOG provides structured early market access for gene therapy products.
- University hospital gene therapy centers support specialized clinical delivery.
- Strong clinical trial participation enables early access to investigational CNS gene therapies.
In-depth Analysis of Gene Therapy in CNS Disorder Market in China
China is expected to grow at 32.0% CAGR through 2036. Government investment in gene therapy manufacturing infrastructure, NMPA regulatory pathway development for cell and gene therapies, and expanding clinical trial activity in CNS indications position China as the second largest gene therapy market globally as domestic and international products gain approval.
- Government investment builds domestic gene therapy manufacturing capacity.
- NMPA regulatory pathway development supports gene therapy product approval.
- Expanding clinical trial activity in CNS indications builds the development pipeline.
Sales Analysis of Gene Therapy in CNS Disorder Market in South Korea
South Korea is expected to grow at 31.0% CAGR through 2036. South Korea's advanced biotechnology infrastructure, MFDS regulatory capabilities for advanced therapy products, and government investment in precision medicine create conditions for early adoption of CNS gene therapies alongside domestic gene therapy development programs.
- Advanced biotechnology infrastructure supports gene therapy manufacturing.
- MFDS regulatory capability enables gene therapy product evaluation and approval.
- Government precision medicine investment creates supportive policy environment.
In-depth Analysis of Gene Therapy in CNS Disorder Market in India
India is expected to grow at 25.0% CAGR through 2036. India's growing biotechnology sector and expanding clinical trial participation create a foundation for CNS gene therapy market development, though access will initially be limited to select tertiary care centers in metropolitan areas where specialist neurology and gene therapy delivery infrastructure is concentrated.
- Growing biotechnology sector creates foundation for gene therapy manufacturing.
- Clinical trial participation provides early access to investigational treatments.
- Tertiary care center concentration limits initial geographic treatment access.
Competitive Landscape and Strategic Positioning
- Novartis has the strongest position in terms of capability and breadth of portfolio.
- Biogen, Spark Therapeutics (Roche) and UniQure compete with specialization and regional expertise.
- Emerging players are focused on niche applications and differentiation.
Technical capability, established relationships and breadth of portfolio give Novartis the strongest competitive position.” The company leverages its multi-regional footprint and regulatory infrastructure.
Biogen, Spark Therapeutics (Roche) and UniQure compete on the basis of specialized capabilities, application expertise and targeted strategies that give them an edge in particular segments or geographies.
Barriers to entry include technical expertise, regulatory compliance costs, established relationships and capital requirements. New entrants attack niche opportunities where incumbents have little coverage.
Strategic priorities include cost optimization, geographic expansion, portfolio extension, and investment in capabilities that strengthen customer retention and recurring revenue.
Key Companies in the Gene Therapy in CNS Disorder Market
Key global companies leading the gene therapy in cns disorder market include:
- Novartis, Biogen, Spark Therapeutics (Roche), UniQure maintain strong positions through integrated capabilities and established relationships.
- Voyager Therapeutics, Sarepta Therapeutics, Neurocrine Biosciences compete through regional specialization and targeted development.
- CRISPR Therapeutics, Pfizer, Sangamo Therapeutics, Vertex Pharmaceuticals, Shape Therapeutics, Samsung Biologics, National Institutes of Health (NIH), Other Key Players are establishing presence through niche focus and differentiation.
Competitive Benchmarking: Gene Therapy in CNS Disorder Market
| Company | Pipeline Depth | Manufacturing Scale | Vector Technology | Regulatory Status |
|---|---|---|---|---|
| Novartis | High | High | Strong | Global |
| Biogen | High | High | Strong | Global |
| Spark Therapeutics (Roche) | High | High | Strong | Global |
| UniQure | Medium | High | Moderate | Global |
| Voyager Therapeutics | Medium | Medium | Moderate | Regional |
| Sarepta Therapeutics | Medium | Medium | Moderate | Regional |
| Neurocrine Biosciences | Low | Medium | Low | Regional |
| CRISPR Therapeutics | Low | Medium | Low | Niche |
| Pfizer | Low | Medium | Low | Niche |
| Sangamo Therapeutics | Low | Medium | Low | Niche |
Source: Future Market Insights competitive analysis, 2026.
Key Developments in Gene Therapy in CNS Disorder Market
- In 2025, Novartis continued advancing its gene therapy pipeline for central nervous system (CNS) disorders, with ongoing clinical progress on Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy (SMA) and early-stage development of AAV-based therapies targeting neurological conditions such as Huntington’s disease and Rett syndrome.
- In 2025, Biogen made significant investments in gene therapy manufacturing capacity and capabilities, particularly to support its collaboration with Sarepta Therapeutics and its own pipeline programs focused on CNS disorders, including potential treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Key Players in the Gene Therapy in CNS Disorder Market
Major Global Players
- Novartis
- Biogen
- Spark Therapeutics (Roche)
- UniQure
- Voyager Therapeutics
- Sarepta Therapeutics
- Neurocrine Biosciences
Emerging Players/Startups
- CRISPR Therapeutics
- Pfizer
- Sangamo Therapeutics
- Vertex Pharmaceuticals
- Shape Therapeutics
- Samsung Biologics
- National Institutes of Health (NIH)
- Other Key Players
Report Scope and Coverage
| Parameter | Details |
|---|---|
| Quantitative Units | USD 18.02 billion to USD 248.39 billion, at a CAGR of 30% |
| Market Definition | The gene therapy in cns disorder market encompasses commercially traded products categorized by Gene Type, Indication, Delivery Method, End User, Vector Type, Route of Administration. |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa |
| Countries Covered | USA, UK, France, Germany, Italy, South Korea, Japan, China, Australia - New Zealand, India, 30 plus countries |
| Key Companies Profiled | Novartis, Biogen, Spark Therapeutics (Roche), UniQure, Voyager Therapeutics, Sarepta Therapeutics, Neurocrine Biosciences, CRISPR Therapeutics, Pfizer, Sangamo Therapeutics, Vertex Pharmaceuticals, Shape Therapeutics, Samsung Biologics, National Institutes of Health (NIH), Other Key Players |
| Forecast Period | 2026 to 2036 |
| Approach | Hybrid bottom up and top down methodology starting with verified transaction data, projecting adoption velocity across segments and regions. |
Segmentation
Gene Therapy in CNS Disorder Market Segmented by Gene Type:
- In Vivo Gene Therapy
- Direct CNS Gene Delivery
- Viral Vector-Based Injections
- Ex Vivo Gene Therapy
- Cell Extraction & Modification
- Re-implantation Therapies
Gene Therapy in CNS Disorder Market Segmented by Indication:
- Alzheimer's Disease
- Amyloid Targeted Gene Therapy
- Neuroprotective Gene Delivery
- Parkinson’s Disease
- Dopamine Pathway Gene Therapy
- Neurorestorative Treatments
- Huntington’s Disease
- Gene Silencing Therapies
- mRNA Targeting Approaches
- Batten Disease
- Lysosomal Storage Disorder Therapy
- Pediatric Neurodegenerative Treatment
Gene Therapy in CNS Disorder Market Segmented by Delivery Method:
- Viral Vectors
- Adeno-Associated Virus (AAV)
- Lentiviral Vectors
- Non-Viral Methods
- Lipid Nanoparticles
- Polymer-Based Delivery Systems
- Direct Injection
- Intracerebral Delivery
- Intrathecal Administration
Gene Therapy in CNS Disorder Market Segmented by End User:
- Hospitals
- Neurology Departments
- Advanced Therapy Centers
- Specialty Clinics
- Neurodegenerative Disease Clinics
- Gene Therapy Centers
Gene Therapy in CNS Disorder Market Segmented by Vector Type:
- Adeno-Associated Virus (AAV)
- AAV2 & AAV9 Serotypes
- CNS-Targeted Viral Vectors
- Lentiviral Vectors
- Stable Gene Integration Systems
- Ex Vivo Cell Modification Vectors
- Retroviral Vectors
- Gene Integration Therapies
- Research-Based Applications
- Non-Viral Vectors
- Lipid Nanoparticles
- Polymeric Gene Delivery Systems
Gene Therapy in CNS Disorder Market Segmented by Route of Administration:
- Intrathecal
- Spinal Fluid Delivery
- Minimally Invasive CNS Access
- Intracerebral
- Direct Brain Injection
- Localized Targeted Therapy
- Intravenous
- Systemic Delivery Approaches
- Blood-Brain Barrier Targeting
Gene Therapy in CNS Disorder Market by Region:
- North America
- USA
- Canada
- Mexico
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Western Europe
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- East Asia
- China
- Japan
- South Korea
- South Asia and Pacific
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- Middle East & Africa
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
Research Sources and Bibliography
- 1. USA Food and Drug Administration. (2025). FDA Guidance: Gene Therapy for Neurological Disorders. FDA.
- 2. European Medicines Agency. (2024). EMA Advanced Therapy Medicinal Products: Gene Therapy Assessment Reports. EMA.
- 3. National Institutes of Health. (2025). NIH Gene Therapy Clinical Trials Database: CNS Disorder Programs. NIH.
- 4. American Society of Gene and Cell Therapy. (2025). ASGCT Gene Therapy Industry Landscape Report. ASGCT.
- 5. World Health Organization. (2025). WHO Expert Committee on Biological Standardization: Gene Therapy Standards. WHO.
This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.
This Report Addresses
- Estimating market size and revenue from 2026 to 2036.
- Segmentation by product, application, end use, and region.
- Insights about more than 30 regional markets.
- Technology, manufacturing, and supply chain analysis.
- Competitive landscape assessment.
- Investment opportunity identification across key segments.
- Supply chain and distribution channel analysis.
- Data delivery in PDF and Excel formats.
Frequently Asked Questions
What is the global market demand for Gene Therapy in CNS Disorder Market in 2026?
In 2026, the global gene therapy in cns disorder market is expected to be worth USD 18.02 billion.
How big will the Gene Therapy in CNS Disorder Market be in 2036?
By 2036, the gene therapy in cns disorder market is expected to reach USD 248.39 billion.
How much is demand for Gene Therapy in CNS Disorder Market expected to grow between 2026 and 2036?
Between 2026 and 2036, demand is expected to grow at a CAGR of 30%.
Which Gene Type is expected to lead in the Gene Therapy in CNS Disorder Market in 2026?
In Vivo Gene Therapy is expected to account for 63.5% of the Gene Type segment in 2026.
What is causing demand to rise in USA in the Gene Therapy in CNS Disorder Market?
USA is expected to grow at 32% CAGR through 2036, supported by domestic scale and favorable conditions.
What is causing demand to rise in China in the Gene Therapy in CNS Disorder Market?
China is expected to grow at 32% CAGR through 2036, driven by established procurement channels.
What does this report mean by 'Gene Therapy in CNS Disorder Market definition'?
The gene therapy in cns disorder market includes all commercially traded products categorized by Gene Type, Indication, Delivery Method, End User, Vector Type, Route of Administration.
How does FMI make the Gene Therapy in CNS Disorder Market forecast?
Forecasting models use a hybrid bottom up and top down approach, starting with verified transaction data and validating against industry statistics and manufacturer disclosures.
Preview the report firsthand - request a free sample
Get SampleGet the brochure for pricing and purchase details.
Get PDFTable of Content
- Executive Summary
- Global Market Outlook
- Demand-side Trends
- Supply-side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
- Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
- Research Methodology
- Chapter Orientation
- Analytical Lens and Working Hypotheses
- Market Structure, Signals, and Trend Drivers
- Benchmarking and Cross-market Comparability
- Market Sizing, Forecasting, and Opportunity Mapping
- Research Design and Evidence Framework
- Desk Research Programme (Secondary Evidence)
- Company Annual and Sustainability Reports
- Peer-reviewed Journals and Academic Literature
- Corporate Websites, Product Literature, and Technical Notes
- Earnings Decks and Investor Briefings
- Statutory Filings and Regulatory Disclosures
- Technical White Papers and Standards Notes
- Trade Journals, Industry Magazines, and Analyst Briefs
- Conference Proceedings, Webinars, and Seminar Materials
- Government Statistics Portals and Public Data Releases
- Press Releases and Reputable Media Coverage
- Specialist Newsletters and Curated Briefings
- Sector Databases and Reference Repositories
- FMI Internal Proprietary Databases and Historical Market Datasets
- Subscription Datasets and Paid Sources
- Social Channels, Communities, and Digital Listening Inputs
- Additional Desk Sources
- Expert Input and Fieldwork (Primary Evidence)
- Primary Modes
- Qualitative Interviews and Expert Elicitation
- Quantitative Surveys and Structured Data Capture
- Blended Approach
- Why Primary Evidence is Used
- Field Techniques
- Interviews
- Surveys
- Focus Groups
- Observational and In-context Research
- Social and Community Interactions
- Stakeholder Universe Engaged
- C-suite Leaders
- Board Members
- Presidents and Vice Presidents
- R&D and Innovation Heads
- Technical Specialists
- Domain Subject-matter Experts
- Scientists
- Physicians and Other Healthcare Professionals
- Governance, Ethics, and Data Stewardship
- Research Ethics
- Data Integrity and Handling
- Primary Modes
- Tooling, Models, and Reference Databases
- Desk Research Programme (Secondary Evidence)
- Data Engineering and Model Build
- Data Acquisition and Ingestion
- Cleaning, Normalisation, and Verification
- Synthesis, Triangulation, and Analysis
- Quality Assurance and Audit Trail
- Market Background
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Trends
- Scenario Forecast
- Demand in Optimistic Scenario
- Demand in Likely Scenario
- Demand in Conservative Scenario
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter’s Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
- Market Dynamics
- Global Market Analysis 2021 to 2025 and Forecast, 2026 to 2036
- Historical Market Size Value (USD Million) Analysis, 2021 to 2025
- Current and Future Market Size Value (USD Million) Projections, 2026 to 2036
- Y-o-Y Growth Trend Analysis
- Absolute $ Opportunity Analysis
- Global Market Pricing Analysis 2021 to 2025 and Forecast 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Gene Type
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Gene Type , 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Gene Type , 2026 to 2036
- In Vivo Gene Therapy
- Direct CNS Gene Delivery
- Viral Vector-Based Injections
- Ex Vivo Gene Therapy
- Cell Extraction & Modification
- Re-implantation Therapies
- In Vivo Gene Therapy
- Y-o-Y Growth Trend Analysis By Gene Type , 2021 to 2025
- Absolute $ Opportunity Analysis By Gene Type , 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Indication
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Indication, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Indication, 2026 to 2036
- Alzheimer's Disease
- Amyloid Targeted Gene Therapy
- Neuroprotective Gene Delivery
- Parkinson’s Disease
- Dopamine Pathway Gene Therapy
- Neurorestorative Treatments
- Huntington’s Disease
- Gene Silencing Therapies
- mRNA Targeting Approaches
- Batten Disease
- Lysosomal Storage Disorder Therapy
- Pediatric Neurodegenerative Treatment
- Alzheimer's Disease
- Y-o-Y Growth Trend Analysis By Indication, 2021 to 2025
- Absolute $ Opportunity Analysis By Indication, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Delivery Method
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Delivery Method, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Delivery Method, 2026 to 2036
- Viral Vectors
- Adeno-Associated Virus (AAV)
- Lentiviral Vectors
- Non-Viral Methods
- Lipid Nanoparticles
- Polymer-Based Delivery Systems
- Direct Injection
- Intracerebral Delivery
- Intrathecal Administration
- Viral Vectors
- Y-o-Y Growth Trend Analysis By Delivery Method, 2021 to 2025
- Absolute $ Opportunity Analysis By Delivery Method, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By End User
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By End User, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By End User, 2026 to 2036
- Hospitals
- Neurology Departments
- Advanced Therapy Centers
- Specialty Clinics
- Neurodegenerative Disease Clinics
- Gene Therapy Centers
- Hospitals
- Y-o-Y Growth Trend Analysis By End User, 2021 to 2025
- Absolute $ Opportunity Analysis By End User, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Vector Type
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Vector Type, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Vector Type, 2026 to 2036
- Adeno-Associated Virus (AAV)
- AAV2 & AAV9 Serotypes
- CNS-Targeted Viral Vectors
- Lentiviral Vectors
- Stable Gene Integration Systems
- Ex Vivo Cell Modification Vectors
- Retroviral Vectors
- Gene Integration Therapies
- Research-Based Applications
- Non-Viral Vectors
- Lipid Nanoparticles
- Polymeric Gene Delivery Systems
- Adeno-Associated Virus (AAV)
- Y-o-Y Growth Trend Analysis By Vector Type, 2021 to 2025
- Absolute $ Opportunity Analysis By Vector Type, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Route of Administration
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Route of Administration, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Route of Administration, 2026 to 2036
- Intrathecal
- Spinal Fluid Delivery
- Minimally Invasive CNS Access
- Intracerebral
- Direct Brain Injection
- Localized Targeted Therapy
- Intravenous
- Systemic Delivery Approaches
- Blood-Brain Barrier Targeting
- Intrathecal
- Y-o-Y Growth Trend Analysis By Route of Administration, 2021 to 2025
- Absolute $ Opportunity Analysis By Route of Administration, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Region
- Introduction
- Historical Market Size Value (USD Million) Analysis By Region, 2021 to 2025
- Current Market Size Value (USD Million) Analysis and Forecast By Region, 2026 to 2036
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia and Pacific
- Middle East & Africa
- Market Attractiveness Analysis By Region
- North America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- USA
- Canada
- Mexico
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- By Country
- Market Attractiveness Analysis
- By Country
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Key Takeaways
- Latin America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Brazil
- Chile
- Rest of Latin America
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- By Country
- Market Attractiveness Analysis
- By Country
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Key Takeaways
- Western Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- By Country
- Market Attractiveness Analysis
- By Country
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Key Takeaways
- Eastern Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- By Country
- Market Attractiveness Analysis
- By Country
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Key Takeaways
- East Asia Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- China
- Japan
- South Korea
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- By Country
- Market Attractiveness Analysis
- By Country
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Key Takeaways
- South Asia and Pacific Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- By Country
- Market Attractiveness Analysis
- By Country
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Key Takeaways
- Middle East & Africa Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- By Country
- Market Attractiveness Analysis
- By Country
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Key Takeaways
- Key Countries Market Analysis
- USA
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Canada
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Mexico
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Brazil
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Chile
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Germany
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- UK
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Italy
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Spain
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- France
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- India
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- ASEAN
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Australia & New Zealand
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- China
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Japan
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- South Korea
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Russia
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Poland
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Hungary
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Kingdom of Saudi Arabia
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Turkiye
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- South Africa
- Pricing Analysis
- Market Share Analysis, 2025
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- USA
- Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
- By Regional
- By Gene Type
- By Indication
- By Delivery Method
- By End User
- By Vector Type
- By Route of Administration
- Competition Analysis
- Competition Deep Dive
- Novartis
- Overview
- Product Portfolio
- Profitability by Market Segments (Product/Age /Sales Channel/Region)
- Sales Footprint
- Strategy Overview
- Marketing Strategy
- Product Strategy
- Channel Strategy
- Biogen
- Spark Therapeutics (Roche)
- UniQure
- Voyager Therapeutics
- Sarepta Therapeutics
- Neurocrine Biosciences
- CRISPR Therapeutics
- Pfizer
- Sangamo Therapeutics
- Vertex Pharmaceuticals
- Shape Therapeutics
- Samsung Biologics
- National Institutes of Health (NIH)
- Other Key Players
- Novartis
- Competition Deep Dive
- Assumptions & Acronyms Used
